Saad Fred
Centre Hospitalier de I'Université de Montréal, Hôpital Notre-Dame, 1560 Rue Sherbrooke East, Montréal, Quebec, Canada PQ H2L 4M1.
Cancer Treat Rev. 2008 Apr;34(2):183-92. doi: 10.1016/j.ctrv.2007.10.002. Epub 2007 Dec 3.
To summarize the current evidence for clinical, anti-tumour, and survival benefits from zoledronic acid in patients with genitourinary cancers.
Studies were identified through MEDLINE searches, review of bibliographies of relevant articles, and review of abstracts from scientific meetings.
Among patients with bone metastases from prostate cancer or renal cell carcinoma, zoledronic acid significantly delayed the onset and reduced the incidence of skeletal complications compared with placebo. Zoledronic acid is also the only bisphosphonate that has demonstrated a trend toward improved survival and delayed progression of bone lesions in patients with urologic malignancies. Furthermore, zoledronic acid reduced the incidence of pathologic fracture, a skeletal-related event known to be associated with reduced survival. Bisphosphonates have also demonstrated significant palliative benefits, and preclinical evidence indicates that bisphosphonates may have direct anti-tumour effects.
Zoledronic acid is the only bisphosphonate that has demonstrated statistically significant, long-term clinical benefits through the prevention and delay of skeletal-related events in patients with metastatic prostate cancer or renal cell carcinoma.
总结唑来膦酸对泌尿生殖系统癌症患者临床、抗肿瘤及生存获益的现有证据。
通过医学文献数据库检索、查阅相关文章的参考文献以及回顾科学会议摘要来确定研究。
在前列腺癌或肾细胞癌骨转移患者中，与安慰剂相比，唑来膦酸显著延迟了骨相关事件的发生并降低了其发生率。唑来膦酸也是唯一一种在泌尿系统恶性肿瘤患者中显示出有改善生存和延迟骨病变进展趋势的双膦酸盐。此外，唑来膦酸降低了病理性骨折的发生率，病理性骨折是一种已知与生存降低相关的骨相关事件。双膦酸盐也已显示出显著的姑息治疗益处，临床前证据表明双膦酸盐可能具有直接抗肿瘤作用。
唑来膦酸是唯一一种通过预防和延迟转移性前列腺癌或肾细胞癌患者的骨相关事件而显示出具有统计学意义的长期临床益处的双膦酸盐。
Zotero 插件